Clinical trials: Neoplasms Recurrence
Prostate Cancer
Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy
The purpose of this research study is to assess the efficacy of antiangiogenic therapy (bevacizumab) and androgen deprivation versus androgen deprivation alone at the time of minimal systemic disease (based on rising PSA without…
- Trial name
- NCT00776594
- Testing
- Androgen Deprivation Therapy, bicalutamide, bevacizumab
- Where
- 8 sites in United States
- Volunteers
- 102 people
- Sponsor
- Dana-Farber Cancer Institute
Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Uterine Corpus Carcinoma
Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer
This phase II trial studies how well enzalutamide, carboplatin, and paclitaxel work in treating patients with endometrioid endometrial cancer that is stage III-IV or has come back.
- Conditions
- Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer AJCC v7, Stage IIIA Uterine Corpus Cancer AJCC v7
- Trial name
- NCT02684227
- Testing
- Carboplatin, Enzalutamide, Laboratory Biomarker Analysis
- Where
- 6 sites in United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer
This phase II trial studies how well celecoxib works through surgery and radiation therapy in treating patients with head and neck cancer that has spread to other places in the body (advanced).
- Conditions
- Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Nasal Cavity and Paranasal Sinus Carcinoma, Oral Cavity Carcinoma
- Trial name
- NCT04162873
- Testing
- Celecoxib, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Utah
Breast Cancer
Chemotherapy Followed by Peripheral Stem Cell Transplantation Plus Biological Therapy in Treating Women With Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation plus biological therapy may allow the doctor…
- Trial name
- NCT00020722
- Testing
- therapeutic autologous lymphocytes, Ifosfamide, carboplatin, and etoposide (ICE) regimen, Cyclophosphamide, Thiotepa, Carboplatin (CTC) or STAMP V (CTC)
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Extrahepatic Bile Duct Adenocarcinoma, Gallbladder Adenocarcinoma
Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma
This phase II trial is studying how well giving sorafenib tosylate together with erlotinib hydrochloride works in treating patients with locally advanced, unresectable, or metastatic gallbladder cancer or cholangiocarcinoma.
- Conditions
- Extrahepatic Bile Duct Adenocarcinoma, Gallbladder Adenocarcinoma, Gallbladder Adenocarcinoma With Squamous Metaplasia, Hilar Cholangiocarcinoma
- Trial name
- NCT01093222
- Testing
- Erlotinib Hydrochloride, Sorafenib Tosylate
- Where
- 141 sites in United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Vaccine Therapy in Treating Patients With Stage III or Stage IV Breast Cancer
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Giving booster vaccinations may make a stronger immune response and kill more tumor cells.
- Trial name
- NCT00304096
- Testing
- synthetic breast cancer peptides-tetanus toxoid-Montanide ISA-51 vaccine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Virginia
Head and Neck Cancer
Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck
The purpose of this study is to determine if IMC-A12 alone or in combination with Cetuximab (Erbitux®) can increase the time prior to disease progression in participants with Squamous Cell Head and Neck Cancer who have had…
- Trial name
- NCT00617734
- Testing
- IMC-A12 (cixutumumab), cetuximab (Erbitux ®)
- Where
- 14 sites in United States
- Volunteers
- 97 people
- Sponsor
- Eli Lilly and Company
Brain Cancer
TPI 287 in Patients With Recurrent Glioblastoma Multiforme
The goal of this clinical research study is to learn if TPI 287 can help to control glioblastoma. The safety of this drug will also be studied.
- Trial name
- NCT01113463
- Testing
- TPI 287
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Hodgkin Lymphoma
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well tazemetostat works in treating patients with brain tumors, solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that have come back (relapsed) or do not respond to…
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma
- Trial name
- NCT03213665
- Testing
- Tazemetostat
- Where
- 117 sites in United States, Puerto Rico
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Mucositis, Oral Complications
Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy
This randomized pilot clinical trial studies whether acetylcysteine oral rinse will lessen saliva thickness and painful mouth sores in patients with head and neck cancer undergoing radiation therapy.
- Conditions
- Mucositis, Oral Complications, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip
- Trial name
- NCT02123511
- Testing
- acetylcysteine, quality-of-life assessment, questionnaire administration
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- Mayo Clinic
Recurrent Adult Soft Tissue Sarcoma, Stage I Adult Soft Tissue Sarcoma AJCC v7
Preoperative Thalidomide With Radiation Therapy For Patients With Low-Grade Primary Soft Tissue Sarcoma or Thalidomide With Radiation Therapy and Chemotherapy For Patients With High-Grade or Intermediate-Grade Primary Soft Tissue Sarcoma of the Arm, Leg, or Body Wall
Thalidomide may stop the growth of soft tissue sarcoma by stopping blood flow to the tumor. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Conditions
- Recurrent Adult Soft Tissue Sarcoma, Stage I Adult Soft Tissue Sarcoma AJCC v7, Stage II Adult Soft Tissue Sarcoma AJCC v7, Stage III Adult Soft Tissue Sarcoma AJCC v7
- Trial name
- NCT00089544
- Testing
- Dacarbazine, Doxorubicin Hydrochloride, Filgrastim
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)
Renal Cell Carcinoma
Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma
Cediranib is being tested to assess its effectiveness on the growth of kidney cancer tumours and also how well it is tolerated.
- Trial name
- NCT00423332
- Testing
- Cediranib
- Where
- 8 sites in Netherlands, United Kingdom
- Volunteers
- 105 people
- Sponsor
- AstraZeneca
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma
This phase II trial studies how well second mitochondrial-derived activator of caspases (SMAC) mimetic LCL161 alone or with cyclophosphamide works in treating patients with multiple myeloma that has returned or does not respond…
- Trial name
- NCT01955434
- Testing
- Cyclophosphamide, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Mayo Clinic
Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-negative Breast Cancer
F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer
This phase II trial is studying how well F-18 16 alpha-fluoroestradiol (FES) imaging works in predicting response to first-line hormone therapy in women with hormone receptor-positive metastatic breast cancer.
- Conditions
- Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT00602043
- Testing
- F-18 16 alpha-fluoroestradiol, fludeoxyglucose F 18, positron emission tomography
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Fallopian Tube Carcinoma, Malignant Ovarian Mixed Epithelial Tumor
A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
This phase II trial is studying the side effects and how well A6 works in treating patients with persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.
- Conditions
- Fallopian Tube Carcinoma, Malignant Ovarian Mixed Epithelial Tumor, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma
- Trial name
- NCT00939809
- Testing
- Urokinase-Derived Peptide A6, Laboratory Biomarker Analysis
- Where
- 16 sites in United States
- Volunteers
- 31 people
- Sponsor
- Gynecologic Oncology Group
Recurrent Breast Cancer, Stage IV Breast Cancer
Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer
Sorafenib may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. Estradiol can cause the growth of breast cancer.
- Trial name
- NCT00217399
- Testing
- sorafenib tosylate, anastrozole
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Sorafenib may stop the growth of tumor cells by blocking the enzymes necessary for their growth and by stopping blood flow to the tumor.
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT00096200
- Testing
- Carboplatin, Paclitaxel, Sorafenib Tosylate
- Where
- 5 sites in United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma
Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
This phase II trial studies the effect of polatuzumab vedotin, venetoclax, and rituximab and hyaluronidase human in treating patients with mantle cell lymphoma that has come back (relapsed) or does not respond to treatment…
- Conditions
- Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma
- Trial name
- NCT04659044
- Testing
- Polatuzumab Vedotin, Rituximab, Rituximab and Hyaluronidase Human
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- Academic and Community Cancer Research United
Metastatic Renal Cell Carcinoma, Renal Cell Carcinoma With Sarcomatoid Features
Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma
RATIONALE: Drugs used in chemotherapy, such as doxorubicin and gemcitabine, use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00068393
- Testing
- Doxorubicin, Gemcitabine, G-CSF (granulocyte-colony stimulating factor)
- Where
- 92 sites in United States
- Volunteers
- 39 people
- Sponsor
- Eastern Cooperative Oncology Group
CD22 Positive, Recurrent Acute Lymphoblastic Leukemia
Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leukemia
This phase II trial studies how well inotuzumab ozogamicin works in treating patients with CD22 positive acute lymphoblastic leukemia that has come back or does not respond to treatment.
- Conditions
- CD22 Positive, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
- Trial name
- NCT03094611
- Testing
- Inotuzumab Ozogamicin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.